Declan Murphy, MB, BCH, BaO, FRACS, FRCS, Urol, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the latest updates in prostate-specific membrane antigen (PSMA) imaging for prostate cancer. Prof. Murphy believes that the FDA approval of PSMA PET-CT imaging for prostate cancer in December 2020, though currently limited to the University of California, Los Angeles, CA, and the University of California, San Francisco, CA, will soon be followed by further approvals of PSMA PET-CT imaging techniques and more widespread access. Prof. Murphy also discusses the results of the prospective randomised proPSMA trial (ANZCTR12617000005358) which compared conventional imaging with CT and bone scanning to gallium-68 PSMA-11 PET-CT. This trial found that PSMA PET-CT had a 27% greater accuracy than conventional imaging and a higher sensitivity and specificity. This interview took place during the 2021 Genitourinary Cancers Symposium.
Declan Murphy, MB, BCH, BaO, FRACS, FRCS, has participated in advisory boards and speaker activities with Janssen, Astellas, Bayer, AstraZeneca, Ferring and Ipsen.